EMERALD-1, 2024 NCT03778957
durvalumab plus bevacizumab (n=204) vs. placebo (n=205)
randomized controlled trial
Durvalumab and Bevacizumab
ACE and then Durvalumab/Bevacizumab
placebo
TACE and then placebo
3 arms TACE and then Durvalumab/Bevacizumab; TACE and then durvalumab/placebo; TACE and then placebo
mHCC - 1st line (L1)
double-blind
results from press release